TTP 889
Latest Information Update: 18 Aug 2015
Price :
$50 *
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor IX inhibitors; Factor IXa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 18 Aug 2015 Discontinued - Phase-II for Thrombosis in USA, Czech Republic, Denmark, Norway and Sweden (PO)
- 15 May 2008 Efficacy and adverse events data from a phase II trial in Thrombosis presented in TransTech Pharma R and D pipeline (15/05/2008)
- 11 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the Thrombosis pharmacodynamics section